Dendreon to Host Conference Call on September 8, 2011 to Discuss Company Restructuring

SEATTLE--(BUSINESS WIRE)--Dendreon Corporation (NASDAQ:DNDN) today announced that management will host a conference call on Thursday, September 8, 2011 at 4:30 p.m. ET to provide a structural and business update on the company.

Access to the discussion may be obtained as follows:

Time: 4:30 p.m. ET / 1:30 p.m. PT

Date: September 8, 2011

Dial-In: (877) 548-9590

International Dial-In: (720) 545-0037

Conference ID: 97761940

Webcast: www.dendreon.com (homepage and investor relations section)

A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-855-859-2056 (toll-free) or 404-537-3406 (international). The replay will be available from 7:30 p.m. ET on September 8 until 11:59 p.m. ET on September 15. In addition the webcast will be archived for on-demand listening for 30 days at www.dendreon.com.

About Dendreon

 Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first product, PROVENGE® (sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in April 2010. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/.

Suggested Articles

BMS' Opdivo-Yervoy combo is playing in an increasingly crowded space. But the company is leaning on new long-term data to set its regimen apart.

GSK and Alcon have pulled off prescription-to-OTC switches in hopes of giving aging brands Voltaren and Pataday a boost.

Sanofi didn't hesitate to enter Zika vaccine R&D, and despite the associated scandal, the company is again jumping into emerging disease vaccine R…